Vaccine by Pfizer and BioNTech (Photo: Getty Images)
a pfizer announced this Tuesday that it will begin testing it Vaccination In the first phase of the study against Covid-19 in a large group of children under the age of 12, after a low dose of vaccine was selected.
According to the company, the research will involve 4,500 children in more than 90 clinics in the United States, Finland, Poland and Spain.
Taking into account the safety, tolerability and immune response produced by 144 children in a phase I study of the two-dose vaccine, Pfizer said it was 10 micrograms for children between the ages of 5 and 11 and for the age group between A dose of 3 micrograms will test. 6 months and 5 years old.
A Pfizer spokesman said the drugmaker expected data for the 5- to 11-year group in September and would likely ask regulatory agencies for authorization for emergency use in the same month. He said that the data of children aged 2-5 years may come soon.
Pfizer expects to have between 6 months and 2 years of data for the group between October and November.
The vaccine, developed by Pfizer and German partner BioNTech, was authorized for use in children 12 years of age and older in Europe, the United States and Canada. They receive the same dosage as adults: 30 micrograms.
According to the US Centers for Disease Control and Prevention, approximately 7 million adolescents in the United States have received at least the first dose of the vaccine.
Henry Lawson is a contributor at Sproutwired.com, covering a wide range of topics including news, politics, business, technology, sport, entertainment and lifestyle. He focuses on delivering clear, accurate and reader-friendly reporting that helps audiences stay informed about current affairs and important developments. With an emphasis on useful information and balanced coverage, Henry aims to highlight stories that matter most to readers, providing context and insight in a straightforward and accessible way.
